TTI-0102

N/A

Report date: 2025/06/05 16:57:44
NME

Base Information

Drug NameTTI-0102
Drug Alias NamePrecursor to cysteamineCysteamine pantetheine disulfidecysteamine-R-pantetheine disulfideTTI-0102
ClassificationSmall molecules
Mechanisms of ActionProtein-glutamine gamma-glutamyltransferase inhibitors
TargetsProtein-glutamine gamma-glutamyltransferase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Stress Disorders, Post-TraumaticRett Syndrome +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVa Office Of Research And Development
China Registration ClassN/A

Develop Information

Active CompaniesThiogenesis Therapeutics Inc
Inactive CompaniesVa Office Of Research And Development
Active IndicationsRett SyndromeLeigh DiseaseMetabolic Dysfunction-Associated Steatotic Liver Disease +[4] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Stress Disorders, Post-TraumaticRespiratory Distress Syndrome, Adult

Other Information

ATC CodeN/A
Related LinksN/A